These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9122911)

  • 1. Food and Drug Administration conference on the feasibility of genetic technology to close the HIV window in donor screening.
    Hewlett IK; Epstein JS
    Transfusion; 1997 Mar; 37(3):346-51. PubMed ID: 9122911
    [No Abstract]   [Full Text] [Related]  

  • 2. [Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors].
    Contreras AM; Reta CB; Torres O; Celis A; Domínguez J
    Salud Publica Mex; 2011; 53 Suppl 1():S13-8. PubMed ID: 21877067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting.
    Roth WK; Weber M; Seifried E
    Lancet; 1999 Jan; 353(9150):359-63. PubMed ID: 9950441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First HIV antigen screening test.
    Am Fam Physician; 1996 Jul; 54(1):376-7. PubMed ID: 8677847
    [No Abstract]   [Full Text] [Related]  

  • 5. The Food and Drug Administration approves second West Nile virus screening test for donated blood and organs.
    Lang L
    Gastroenterology; 2007 Nov; 133(5):1402. PubMed ID: 17983794
    [No Abstract]   [Full Text] [Related]  

  • 6. Relative sensitivity of United States and European assays for screening blood donors for antibodies to human immunodeficiency viruses.
    Busch MP; Couroucé AM
    Transfusion; 1997 Mar; 37(3):352-4. PubMed ID: 9122912
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnostic accuracy of blood centers in the screening of blood donors for viral markers.
    Dogbe EE; Arthur F
    Pan Afr Med J; 2015; 20():119. PubMed ID: 26090067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fourth-generation enzyme immunoassays for screening of HIV in blood donors: need of the hour.
    Kaur R; Basu S; Kaur G; Singh D
    Indian J Pathol Microbiol; 2011; 54(2):433-4. PubMed ID: 21623129
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of chemiluminescent enzyme immunoassay screening for human parvovirus B19 antigen in Japanese blood donors.
    Sakata H; Matsubayashi K; Ihara H; Sato S; Kato T; Wakisaka A; Tadokoro K; Yu MY; Baylis SA; Ikeda H; Takamoto S
    Transfusion; 2013 Oct; 53(10 Pt 2):2556-66. PubMed ID: 23145866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TaqMan 5'-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening.
    Drosten C; Seifried E; Roth WK
    J Clin Microbiol; 2001 Dec; 39(12):4302-8. PubMed ID: 11724836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whose blood is safer? The effect of the stage of the epidemic on screening for HIV.
    Litvak E; Siegel JE; Pauker SG; Lallemant M; Fineberg HV; Weinstein MC
    Med Decis Making; 1997; 17(4):455-63. PubMed ID: 9343804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
    Nübling CM; Chudy M; Volkers P; Löwer J
    Transfusion; 2006 Nov; 46(11):1886-91. PubMed ID: 17076842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period.
    Ling AE; Robbins KE; Brown TM; Dunmire V; Thoe SY; Wong SY; Leo YS; Teo D; Gallarda J; Phelps B; Chamberland ME; Busch MP; Folks TM; Kalish ML
    JAMA; 2000 Jul; 284(2):210-4. PubMed ID: 10889595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First HIV 'window period' donation in a UK blood donor.
    Morris K; Webb B; Dow B; McClelland M; Jordan T; Jarvis L
    Transfus Med; 2005 Jun; 15(3):249-50. PubMed ID: 15943712
    [No Abstract]   [Full Text] [Related]  

  • 15. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group.
    Busch MP; Dodd RY; Lackritz EM; AuBuchon JP; Birkmeyer JD; Petersen LR
    Transfusion; 1997 Oct; 37(10):1003-11. PubMed ID: 9354817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in postmortem blood specimens using infectious disease assays licensed for cadaveric donor screening.
    Greenwald MA; Kerby S; Francis K; Noller AC; Gormley WT; Biswas R; Forshee RA
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29178465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 viral load test approved by FDA.
    AIDS Patient Care STDS; 2007 Jun; 21(6):438-9. PubMed ID: 17594254
    [No Abstract]   [Full Text] [Related]  

  • 18. Interim recommendations for deferral of donors at increased risk for HIV-1 Group O infection; guidance document; availability--FDA. Notice.
    Fed Regist; 1997 Sep; 62(184):49695. PubMed ID: 10173802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV antigen detection in routine blood donor screening.
    Stute R
    Lancet; 1987 Mar; 1(8532):566. PubMed ID: 2881115
    [No Abstract]   [Full Text] [Related]  

  • 20. [New test for determination of HIV-1 RNA level].
    Dtsch Med Wochenschr; 2003 Aug; 128(31-32):1680. PubMed ID: 12931729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.